Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
METHOD FOR ASSESSING LIKELIHOOD OF CHRONIC KIDNEY DISEASE PATIENT DEVELOPING HYPERPHOSPHATEMIA
Document Type and Number:
WIPO Patent Application WO/2017/159473
Kind Code:
A1
Abstract:
Provided is a method for assessing the likelihood of a chronic kidney disease (CKD) patient developing hyperphosphatemia by measuring the fibroblast growth factor 23 (FGF-23) in samples collected from the CKD patient and comparing the measurement with the standard that if the FGF-23 concentration in the sample is equal to or above a reference value, the CKD patient is likely to develop hyperphosphatemia, and if the concentration is below the reference value, the CKD patient is unlikely to develop hyperphosphatemia. The method for assessing the likelihood of a CKD patient developing hyperphosphatemia according to the present invention is useful in clinical diagnosis.

Inventors:
KIMURA TAKEHIDE (JP)
SHINODA TATSUYA (JP)
Application Number:
PCT/JP2017/009145
Publication Date:
September 21, 2017
Filing Date:
March 08, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
KYOWA MEDEX CO LTD (JP)
International Classes:
G01N33/68
Domestic Patent References:
WO2003057733A12003-07-17
Other References:
KURO-O, M., PHOSPHATE AND KLOTHO, KIDNEY INTERNATIONAL, vol. 79, no. 21, April 2011 (2011-04-01), pages S20 - S23, XP055421587
GUTIERREZ, O. ET AL.: "Fibroblast Growth Factor- 23 Mitigates Hyperphosphatemia but Accentuates Calcitriol Deficiency in Chronic Kidney Disease", J OURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 16, no. 7, 1 July 2005 (2005-07-01), pages 2205 - 2215, XP002484714
Attorney, Agent or Firm:
HARUNA, Masao et al. (JP)
Download PDF: